Ascendia

  MARKET NEWS

Credence MedSystems Announces Commercial Supply Agreement With Global Biopharmaceutical Leader
Roswell Park Study Shows IL-36 Gamma "Armored" CAR T Cells Can Eradicate Solid Tumors
Verista Expands Automation & Validation Capabilities With Acquisition of Integral Solutions
Sharp Sterile Manufacturing Increases Capacity With $28-Million Investment
ProBioGen & Zag Bio Forge Strategic CMC Partnership to Advance Fc-Fusion Autoimmune Therapy
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL (obe-cel) on the Cellares Cell Shuttle Platform
Nimbus Therapeutics Announces Research Collaboration & License Agreement With Lilly for Novel Oral Obesity Treatment
FDA Approves New 2-Gram Presentation of Fibryga, Enhancing Convenience & Precision in Treating Acquired Fibrinogen Deficiency
Zenas BioPharma Announces Positive Results from Phase 3 Trial of Obexelimab in Immunoglobulin G4-Related Disease
Protara Therapeutics Receives Both FDA Breakthrough Therapy & Fast Track Designations for TARA-002 in Pediatric Patients With Lymphatic Malformations

  EXPERT CONTENT & RESOURCES

Life Sciences in 2025: Strategic Recalibration & What's Next

Life Sciences in 2025: Strategic Recalibration & What's Next

Those who succeed in 2026 will be the organizations that set a bold vision, empower cross-functional collaboration, and stay committed to continuous innovation. The future of life sciences is one of extraordinary promise – and the recalibration underway today is setting the foundation for a healthier world tomorrow.

The AI-Driven Path to Precision Therapeutics

The AI-Driven Path to Precision Therapeutics

Drs. Rotem Gura-Sadovsky and Maayan Eilon-Ashkenazy explore the potential for AI to transform drug discovery, charting a path towards more targeted precision therapeutics.

How PolyPid’s PLEX Unlocks the Potential of Local & Prolonged Release

How PolyPid’s PLEX Unlocks the Potential of Local & Prolonged Release

This article answers the question: what if, instead of relying on systemic delivery, we could create a platform that anchors drugs directly at the site of need and controls its release over weeks or months?

To Improve Upon a Miracle Drug: Overcoming Drug Resistance & Intolerance in CML

To Improve Upon a Miracle Drug: Overcoming Drug Resistance & Intolerance in CML

Thanks to the pioneering work of researchers advancing our knowledge of basic science and cancer, the field has been able to transform the lives of millions of patients with CML. But challenges remain, and everyone in the industry strives to improve upon the “miracle drug” imatinib, that was approved almost 25 years ago.

  FEATURED EDITORIAL

  COMPANY PROFILE

Sharp is a leading global provider of commercial packaging, clinical supply services and sterile manufacturing solutions for the pharmaceutical and biotechnology industries. For over 70 years, we have partnered with clients across every phase of the drug development journey — from early-phase clinical trials through to commercial launch and lifecycle management. Our mission is to support our clients in delivering life-changing therapies safely, efficiently and compliantly to patients worldwide. Click here for more.

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR: Drug Product Design for Delivery of Challenging Molecules

ON-DEMAND WEBINAR: Drug Product Design for Delivery of Challenging Molecules

In this talk we illustrate several case studies demonstrating how a fundamental understanding of molecular properties combined with a strategic vision for drug product design can lead to effective and advanceable formulations for even the most challenging drug products.

vytal webinar

WEBINAR - Vytal: The RTU Snap-Fit System for Container Closure Solutions – Setting the Standard for the Future

In recent decades, the landscape of parenteral drug production has undergone significant transformation, driven by the emergence of novel molecules and advanced therapies. The pharmaceutical industry has witnessed a notable shift towards biologics, mAbs, and cell-based therapies, which now represent some of the most successful pharmaceutical products globally.

  WHITEPAPERS & WEBINARS

WHITEPAPER - 3D Reconstructed Skin Models: Transforming Clinical & Safety Testing

WHITEPAPER - 3D Reconstructed Skin Models: Transforming Clinical & Safety Testing

SGS, the world’s leading testing, inspection and certification company, recently announced the release of a new white paper, 3D Reconstructed Skin Models: Transforming Clinical & Safety Testing.

Targeted at researchers, toxicologists and formulation scientists in the clinical and dermatological …

WHITEPAPER - An Insoluble Problem? Overcoming Oral Drug Solubility Challenges With Functional Polymers

WHITEPAPER - An Insoluble Problem? Overcoming Oral Drug Solubility Challenges With Functional Polymers

 

The biopharmaceutical classification system classifies drugs according to their permeability and solubility. Drugs with poor solubility and/or permeability are class II or IV type drugs, and these require special formulation technologies for solubility enhancement. In the past 25 …

WHITEPAPER - Advancements in Intradermal Delivery: From Historic Techniques to Modern Innovations

WHITEPAPER - Advancements in Intradermal Delivery: From Historic Techniques to Modern Innovations

Abstract

Intradermal delivery has long been a critical method in medical and pharmaceutical fields, offering unique advantages for diagnosis, vaccination and therapeutic applications. This white paper explores the evolution of intradermal delivery methods, comparing historic methods of delivery such as …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

January 14 – Excipients
January 21 – Drug Delivery